Taysha Gene Therapies Files 8-K/A Amendment
Ticker: TSHA · Form: 8-K/A · Filed: May 29, 2025 · CIK: 1806310
| Field | Detail |
|---|---|
| Company | Taysha Gene Therapies, Inc. (TSHA) |
| Form Type | 8-K/A |
| Filed Date | May 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, sec-filing, regulation-fd
TL;DR
Taysha Gene Therapies filed an amendment to an 8-K, likely clarifying previous disclosures.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K/A amendment on May 29, 2025, related to events reported on May 28, 2025. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing is an amendment to a previous report, indicating Taysha Gene Therapies is providing updated or corrected information to the SEC, which could be material to investors.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material information or significant financial changes in the provided excerpt.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- May 28, 2025 (date) — Earliest event reported date
- May 29, 2025 (date) — Filing date
- 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed 8-K report, updating information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on May 28, 2025.
What is Taysha Gene Therapies, Inc.'s principal executive office address?
Taysha Gene Therapies, Inc.'s principal executive office is located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SIC code for Taysha Gene Therapies, Inc.?
The Standard Industrial Classification (SIC) code for Taysha Gene Therapies, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on May 29, 2025 regarding Taysha Gene Therapies, Inc. (TSHA).